As a result of these difficulties they could not undertake a review to assess the outcomes of these drugs on patients.
The UK team, led by Robert Fleetcroft from Norwich Medical School at the University of East Anglia, argues that "difficulty accessing data from clinical trials means that only part of the evidence base is available" and this may lead to "erroneous clinical decisions."